Bispecific PD-1 and TIGIT binding proteins and uses thereof

US11939382B2 · kind B2 · utility

Assignee

• MedImmune Limited · US

Inventors

• Yariv Mazor · Austin, US
• Yue Wang · Beijing, CN
• GORDON MOODY · Gaithersburg, US
• Deepali Malhotra · Minneapolis, US
• Michael Glen Overstreet · Gaithersburg, US
• Eleanor CLANCY-THOMPSON · Gaithersburg, US
• Karin L. Lee · Cleveland, US
• Stacy PRYTS · Gaithersburg, US
• Scott Hammond · Gaithersburg, US

Key dates

• Filing date: Apr 29, 2022
• Grant date: Mar 26, 2024
• Expiry date: Apr 29, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.